Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: An analysis of 168 cases

Journal of Clinical Pathology

Volumn 52, Issue 8, 1999, Pages 574-580

  Korshunov, Andrey ^a   Golanov, Andrey ^a   Sycheva, Regina ^a   Pronin, Igor ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

Apoptosis; Epidermal growth factor receptor; Glioblastoma

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; TUMOR ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032794642     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.8.574     Document Type: Article

References (56)

1. Burger PC, Green SB. Patient age, histological features and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25.
2. Ganju V, Jenkins RB, O'Fallon JR, et al. Prognostic factors in gliomas. A multivariate analysis of clinical pathological, flow cytometric, cytogenetic, and molecular markers. Cancer 1994;74:920-7.
3. Cohadon F, Aouad N, Rougier A, et al. Histologic and non- histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neurooncol 1985;3:105-11.
4. Salcman M, Scholtz H, Kaplan RS, et al. Long-term survival in patients with malignant astrocytoma. Neurosurgery 1994; 34:213-20.
5. Ang LC, Plewes M, Tan L, et al. Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 1994;21:306-10.
6. Baxendine-Jones J, Campbell T, Ellison D. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 1997;16:332-6.
7. Chozick BS, Pezullo JC, Epstein MH, et al. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors, Neurosurgery 1994;35:831-8.
8. Cunningham JM, Kimmel DW, Scheithauer BW, et al. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997;86:121-30.
9. Diedrich U, Lucius J, Baron E, et al. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 1995;242: 638-88.
10. Ehrmann JJ, Kolyr Z, Vojtesek B. Prognostic factors in astrocytomas: relationship of p53, MDM2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 1997;44:299-304.
11. Jaros E, Perry RH, Adam L, et al. Prognostic implication of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumor. Br J Cancer 1992;66:373-85.
12. Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferating markers and epidermal growth factors receptor. Br J Cancer 1997;75:1269-78.
13. Kyritsis AP, Xu R, Bondy ML, et al Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinogen 1996;15:14-18.
14. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms, Neurosurgery 1994;34: 674-9.
15. Pigott TJD, Lowe JS, Palmer J. Statistical modeling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. Br J Neurosurg 1991;5:61-6.
16. Rainov NG, Dobberstein KU, Bahn H, et al. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 1997;35:13-28.
17. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin- embedded samples. J Pathol 1994;174:275-82.
18. Schober R, Bilzer T, Waha A, et al. The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression and patient survival data in a therapeutic trial. Clin Neuropathol 1995;14:169-74.
19. Soini Y, Nyemela A, Kamel D, et al. p53 immunohistochemical positively as a prognostic marker in intracranial tumours. APMIS 1993;102:786-92.
20. Stemmer Rachamimov AO, Louis DN, Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 1997;9:210-4.
21. Theunissen PHMH, Blaauw J. Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytomas, Histopathology 1993;23:75-9.
22. Waha A, Baumann A, Wolf HK, et al. Lack of prognostic relevance of alterations in epidermal growth factor receptor- transforming growth factor a pathway in human astrocytic gliomas. J Neurosurg 1996;85:634-41.
23. Zhu A, Shaeffer J, Leslie S. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive radiation. Int J Radiat Oncol Biol Phys 1996;34:809-15.
24. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system: World Health Organization international classification of tumour. Berlin: Springer, 1993.
25. Kaplan ER, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
26. Segal MR. Regression trees for censored data. Biometrics 1988;44:35-47.
27. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972;34:187-220.
28. Levine AJ: Tumor suppressor genes. In: Levine AJ, Schmidek HH, eds. Molecular genetics of nervous system tumors. New York: Wiley Liss, 1993:137-43.
29. Savitz SI, Rosenbaum DM. Apoptosis in neurological disease. Neurosurgery 1998;42:555-74.
30. Haas-Kogan DA, Yount G, Haas M, et al. p53-dependent G 1 arrest and p53 independent apoptosis influence the radiobiologic response of glioblastoma, Int J Radiat Oncol Biol Phys 1996;36:95-103.
31. Carrol RS, Zhang J, Chauncey BW. Apoptosis in astrocytic neoplasms. Acta Neurochir (Wien) 1997;139:845-50.
32. Ellison DW, Steart PV, Gatter KC, et al. Apoptosis in cerebral astrocytic tumors and its relationship to expression of BCL-2 and p53 proteins. Neuropathol Appl Neurobiol 1995;21:352-61.
33. Krajewski S, Krajewska M, Ehramann J, et al. Immunohistochemical analysis of Bcl-2, Bcl-X, MCl-1 and Bax in tumors of central and peripheral nervous system. Am J Pathol 1997;150:805-14.
34. Krishna M, Smith TW, Recht LD, Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence of degree of malignancy. J Neurosurg 1995;83: 1017-22.
35. Nakasu S, Nakasu Y, Nioka H, et al. Bel-2 protein expression in tumors of the central nervous system. Acta Neuropathol (Berl) 1994;88:520-6.
36. Schiffer D, Cavalla P, Migheli A, et al. Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neurooncol 1996;27:101-9.
37. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2 and bax oncoproteins and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997;15:2456-66.
38. Berardo MD, Elledge RM, de Moor C, et al. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998;82:1296-302.
39. Kaklamanis L, Savage A, Whitehouse R, et al. Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. Br J Cancer 1998;77:1864-9.
40. Zhang GJ, Kimijima I, Watanabe T, et al. [Correlation between apoptotic index, bcl 2 protein expression and progression and prognosis in breast carcinoma]. Gan To Kagaku Ryoho 1998;25:415-21 [in Japanese].
41. Weiner H. The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 1995;37:179-94.
42. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26.
43. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56:5079-86.
44. Ekstrand AJ, Longo N, Hamid ML, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastoma with EGFR gene amplification. Oncogene 1994;9:2313-20.
45. Kordek R, Hironoshi N, Liberski PP, et al. Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Acta Neuropathol (Berl) 1996;91:112-16.
46. Kokunai T, Sawa H, Tamaki N. Localization of apoptotic cells in situ of brain tumors. Brain Tumor Pathol 1995;12:15-21.
47. Migheli A, Cavalla P, Marino S, et al. A study of apoptosis in normal and pathological nervous tissue alter in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994;53:606-16.
48. Patsouris E, Davaki P, Kapranos N, et al. A study of apoptosis in brain tumors by in situ end-labelling method. Clin Neuropathol 1996;15:337-41.
49. Tachibana O, Lampe J, Kleihues P, et al. Preferential expression of Fas/APO (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 1996;92:431-4.
50. Nakasu S, Nakajima M, Nakazava T, et al. Alteration of bcl-2 and bax expression in embolized meningiomas. Brain Tumor Pathol 1998;15:13-17.
51. Imitola J, Nikas DS, Black PMCL. Apoptosis in tumors of the central nervous system. Crit Rev Neurosurg 1997;7: 391-9.
52. Nakatsu S, Kondo S, Yin D, et al. Induction of apoptosis in multi-drug resistance (MDR) human glioblastoma cells by SN-38, a metabolite of the campothecin deprivate CTP 11. Cancer Chemother Pharmacol 1997;71:417-23.
53. Komaki R, Fujii T, Perkins P, et al. Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1996;36: 601-5.
54. Yamasaki F, Tokunaga O, Sugimori H. Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 1997;66:439-48.
55. Kaufmann AM, Lichtner RB, Schirrmacher V, et al. Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Oncogene 1996;13:2349-58.
56. Matsuda H, Strebel FR, Kaneko T, et al. Apoptosis and necrosis occurring during different stages of primary and metastatic tumor growth of a rat mammary adenocarcinoma. Anticancer Res 1996;16:1117-21.